Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest Adenocarcinoma Stories

2013-08-26 10:56:35

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies. The study, published August 23, 2013 in the online version of the journal Cancer by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH), is the first to compare the spectrum of cancer-related gene mutations in the two main subtypes of...

Genetic Vulnerability Of Lung Cancer To Lay Foundation For New Therapies
2013-04-04 13:40:06

UT Southwestern Medical Center Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells — a specific genetic weakness that can be exploited for new therapies. Although researchers have long known that mutant versions of the KRAS gene drive tumor formation and are key to cell survival in non-small cell lung cancer, the blocking of activated KRAS has proven difficult. For years, investigations have explored stopping lung...

2012-11-30 16:11:11

A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages. Research led by scientists at the University of California, San Diego and UC San Francisco Schools of Medicine examined the tumor-initiating events leading to pancreatic cancer (also called pancreatic ductal adenocarcinoma or PDA) in mice. Their work, published on line November 29 in the journal Cancer Cell, may help in...

2012-08-23 23:41:04

Common, but as yet unidentified factor, behind sudden surge in cases around the world A global assessment of the oesophageal adenocarcinoma epidemic The global "epidemic" of one type of gullet cancer (adenocarcinoma) seems to have started in the UK during the 1950s, sparked by some as yet unknown, but common, factor, suggests research published online in Gut. There are two distinct types of gullet (oesophageal) cancer–squamous and adenocarcinoma, the latter typically affecting...

2012-06-27 17:31:18

Comprehensive strategy includes more accurate CT scan analysis, complex surgical technique Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients. Pancreatic adenocarcinoma is one of the most devastating forms of pancreatic cancer with survival rates of only 5 percent at five years. Surgical removal...

2012-06-04 02:26:41

INDIANAPOLIS, June 4, 2012 /PRNewswire/ -- Final results from PARAMOUNT, a Phase III study of ALIMTA(® )(pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY). PARAMOUNT results will be presented on Monday, June 4, at the 48th Annual...

2012-05-17 12:41:57

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas – the most common type of non-small cell lung cancer – and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung...

2012-04-30 02:24:42

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers(1-3), and in 23% of all solid tumors(4). The Company intends to establish and validate the performance of...

2012-04-03 09:10:45

The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found. The supplement, a fatty acid also known as GLA, worked particularly well when combined with the chemotherapy drug gemcitabine, the researchers say. The findings were presented today by Mayo Clinic pathologist Ruth Lupu, Ph.D., at the American Association for Cancer Research (AACR) Annual Meeting 2012. "One of...

2012-03-21 00:38:11

New study shows how to defeat chemotherapy barrier in nation's 4th deadliest cancer Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer. A unique biological barrier that pancreatic cancer tumors build around themselves have made them especially resistant to chemotherapy treatments, according to the Hutchinson Center/TGen study published today in the highly-regarded...